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Abstract
This study examined the cardiovascular effects of GLP-1 (7–36) or (9–36) on myocardial oxygen 
consumption, function and systemic hemodynamics in vivo during normal perfusion and during 
acute, regional myocardial ischemia. Lean Ossabaw swine received systemic infusions of saline 
vehicle or GLP-1 (7–36 or 9–36) at 1.5, 3.0, and 10.0 pmol/kg/min in sequence for 30 min at each 
dose, followed by ligation of the left circumflex artery during continued infusion at 10.0 pmol/kg/
min. Systemic GLP-1 (9–36) had no effect on coronary flow, blood pressure, heart rate or indices 
of cardiac function before or during regional myocardial ischemia. Systemic GLP-1 (7–36) 
exerted no cardiometabolic or hemodynamic effects prior to ischemia. During ischemia, GLP-1 
(7–36) increased cardiac output by approximately 2 L/min relative to vehicle-controls (p=0.003). 
This response was not diminished by treatment with the non-depolarizing ganglionic blocker 
hexamethonium. Left ventricular pressure-volume loops measured during steady state conditions 
with graded occlusion of the inferior vena cava to assess load-independent contractility revealed 
that GLP-1 (7–36) produced marked increases in end diastolic volume (74 ± 1 to 92 ± 5 mL; 
p=0.03) and volume axis intercept (8 ± 2 to 26 ± 8; p=0.05), without any change in the slope of 
the end systolic pressure volume relationship vs. vehicle during regional ischemia. GLP-1 (9–36) 
produced no changes in any of these parameters compared to vehicle. These findings indicate that 
short-term systemic treatment with GLP-1 (7–36) but not GLP-1 (9–36) significantly augments 
cardiac output during regional myocardial ischemia, via increases in ventricular preload without 
changes in cardiac inotropy.
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INTRODUCTION
Full length GLP-1 (7–36), endogenously produced by intestinal L-cells, is generally 
considered to be the physiologically active form of GLP-1 [11]. Administration of GLP-1 
(7–36) results in proportional increases in circulating GLP-1 (9–36) levels [21;40]. Data on 
cardiovascular effects of these peptides are mixed: Infusion of the (7–36) or (9–36) peptide 
have produced increased [3;31], decreased [24;26;36;41], or no change [19;28;35] in cardiac 
contractile function in normal hearts in rats, dogs and pigs. Effects of GLP-1 (7–36) or (9–
36) to augment preload-dependent indices of cardiac function in ischemic and failing hearts 
[2;27–29;41] have been more clearly demonstrated, although again this effect is not 
consistently observed [30;38]. Importantly, no study to date has directly assessed preload-
independent measures of cardiac contractility in either normal or ischemic hearts. Therefore, 
whether improvements in cardiac contractile function induced by GLP-1 are mediated by 
direct inotropic effects, increases in ventricular diastolic filling (i.e. Frank-Starling effects), 
and/or cardioprotective mitigation of ischemic injury has not been defined.
This set of studies was designed to evaluate the dose-dependent effects of GLP-1 (7–36) or 
(9–36) (1.5 – 10.0 pmol/kg/min, iv) on systemic hemodynamics, coronary flow, cardiac 
metabolism and preload-dependent and -independent measures of cardiac function in normal 
vs. ischemic hearts. Left ventricular pressure volume relations were assessed in lean 
Ossabaw swine with high-resolution admittance catheters before and during acute ligation of 
the left circumflex coronary artery. Inotropic status was directly evaluated by measuring the 
slope of the end-systolic pressure-volume relationship, using brief balloon occlusion of the 
inferior vena cava to produce graded reductions of ventricular preload. Our findings provide 
novel insight into the differential cardiovascular actions of GLP-1 isoforms and have 
important implications for the use of incretin-based therapies in circumstances of impaired 
cardiac function or ischemia.
METHODS
All protocols were approved by the Institutional Animal Care and Use Committee in 
accordance with the Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85–
23, Revised 1996) and have therefore been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later amendments. Ossabaw 
Swine (n = 23) weighing between 66kg and 83kg were initially sedated with Telazol 
(tiletamin-zolazepam, 5mg/kg sc), xylazine (2.2mg/kg sc), and ketamine (3.0 mg/kg sc). 
Subsequent to endotracheal intubation and venous access, anesthesia was maintained with 
morphine (3.0mg/kg sc) and α-chloralose (100mg/kg, i.v.). Animals were mechanically 
ventilated (Harvard respirator) with O2 supplemented room air. Following completion of 
experimental protocols, hearts were fibrillated and excised in accordance with 
recommendation of the American Veterinary Medical Association Guide on Euthanasia 
(June 2007).
Surgical preparation
Acute in-vivo experiments were conducted in open chest, anesthetized pigs. Catheters were 
placed into the right femoral artery and vein for systemic hemodynamic measurements and 
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administration of supplemental anesthesia, heparin and sodium bicarbonate respectively. A 
Fogarty balloon catheter (Edwards Lifesciences) was introduced into the left femoral vein 
and advanced into the inferior vena cava to allow for experimental reduction of venous 
return to the heart. Blood gas parameters were maintained within normal limits through 
periodic arterial blood gas analyses and appropriate adjustments to breathing rate and 
bicarbonate supplementation as necessary (arterial PO2 = 180 ± 63 mmHg; arterial PCO2 = 
42 ± 1; pH = 7.4 ± 0.01; hematocrit = 35 ± 4). A left lateral thoracotomy was performed, 
allowing for access to the heart. The left circumflex artery (LCX) was then isolated and a 
suture placed loosely around it. At appropriate points in the study, this suture was used to 
ligate the LCX, thereby inducing regional myocardial ischemia. Next, the left anterior 
descending artery (LAD) was isolated and a perivascular flow transducer (Transonic 
Systems Inc.) was placed around the vessel. Following flow probe placement, a catheter was 
introduced into the coronary interventricular vein for coronary venous blood sampling. A 
pericardial cradle was then made to allow for adequate access to the heart apex and a purse 
string suture was placed at the apex through which an 18 gauge needle was passed into the 
LV cavity to allow for introduction and securing of a pressure volume admittance catheter 
(Transonic Systems). All data were collected using IOX acquisition software (EMKA 
Technologies, Falls Church VA. USA). Prior to any measurements, heparin was 
administered (bolus; 500 U/kg, iv) to prevent formation of blood clots during the protocol.
Experimental Protocol
Animals were randomly assigned to study infusions, with no differences in pre-treatment 
management, surgical preparation, or study procedures other than the study infusion. A total 
of n=23 animals were studied. This study employed four groups; vehicle treated (n=5), 
GLP-1 (7–36) treated (n=9), GLP-1 (9–36) treated (n=5), GLP-1 (7–36) treated with 
concurrent hexamethonium (5 mg/kg, iv) administration (n=3), and a single animal who was 
treated with epinephrine (n=1). Following a stabilization period of at least 20 min, animals 
received continuous intravenous infusions of vehicle (saline), or graded infusions of 
increasing concentrations of GLP-1 (7–36) or GLP-1 (9–36) at 1.5, 3.0, and 10.0 
pmol/kg/min in sequence for 30 min at each dose. Following these infusions, the 10 
pmol/kg/min was continued and the left coronary artery (LCX) was ligated to induce 
regional ischemia for an additional 30 min. In swine this ligation affects ~20% of the left 
ventricle [12]. The same animals that received graded vehicle or GLP-1 dosing also received 
coronary occlusion. However, only n=5 of the GLP-1 (7–36) treated animals were subjected 
to coronary ligation (i.e. 5 of the 9 GLP-1 (7–36) treated pigs received LCX occlusion).
Aortic pressure, left ventricular pressure, left ventricular volume, coronary blood flow 
(LAD) and ECG were measured throughout the entire protocol. The left ventricular end-
systolic pressure volume relationship was assessed at each of the 30 minute time points by a 
brief inflation (< 5 sec) of the Fogarty balloon catheter to reduce venous return. Similar 
pressure volume measurements were performed in the animal treated with epinephrine 
(10µg/min) to demonstrate as a positive control the effects of a known inotrope on left 
ventricular pressure volume relationships measured using this methodology.
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Metabolic Analysis
Arterial and coronary venous blood were collected simultaneously into untreated syringes, 
immediately sealed, and placed on ice. These samples were analyzed for pH, PCO2, PO2, O2 
content, and hematocrit with an Instrumentation Laboratories automatic blood gas analyzer 
(GEM Premier 3000) and CO-oximeter (682) system. Myocardial oxygen consumption (µl 
O2/min/g) was calculated using the Fick principle as [coronary blood flow × (arterial O2 
content – coronary venous O2 content)]. For these calculations, LAD perfusion territory was 
estimated to be 30% of total heart weight, as previously described by Feigl et al. [12]. 
Cardiac efficiency was calculated as the product of cardiac output (L/min) and mean arterial 
pressure (mmHg) divided by myocardial oxygen consumption (µl O2/min/g).
Statistical Analyses
Data are presented as mean ± SE. Statistical comparisons were made with two way 
(ANOVA) testing for differences between treatments in the dose response, and with one-
way ANOVA comparing treatment groups under ischemia or comparing values within a 
treatment group before and after ischemia. For all comparisons, P ≤ 0.05 was considered 
statistically significant. When significance was found with ANOVA, a Student-Newman-
Keuls multiple comparison test was performed to identify differences between treatment 
levels and/or GLP-1 (7–36) or (9–36) vs. saline infused time controls.
RESULTS
Hemodynamic and Metabolic Effects of Acute GLP-1 Administration
Effects of GLP-1 (7–36), GLP-1 (9–36) and time control saline infusions on systemic 
hemodynamic variables are listed in Table 1. Despite randomization to treatment conditions, 
modest (non-significant) differences in baseline blood pressure and heart rate were present 
between the treatment groups prior to GLP-1 administration. To avoid any bias resulting 
from this, we present results as absolute changes in these variables (Figure 1). We observed 
a time-dependent fall in blood pressure over the course of the experimental protocol that did 
not differ between groups (Figure 1). Acute coronary occlusion had little additional effect on 
mean blood pressure in control or GLP-1 (9–36) treated swine (Figure 1C). However, acute 
coronary occlusion was associated with a significant further decrease in mean blood 
pressure in GLP-1 (7–36) treated animals (P < 0.001). This decrease in arterial pressure was 
associated with a ~20 beat/min increase in heart rate in GLP-1 (7–36) treated swine relative 
to identically handled saline-infused time control animals (Figure 1D; P = 0.001).
Consistent with the changes in blood pressure, coronary flow and myocardial oxygen 
consumption in the non-ischemic LAD region tended to decrease in all treatment groups 
(Table 1). Reductions in coronary flow were statistically greater relative to within group 
baseline in GLP-1(7–36) treated swine at the 3.0 (P = 0.006) and 10.0 pmol/kg/min (P = 
0.019) exposure as well as during regional myocardial ischemia (P = 0.013). However, 
absolute coronary blood flows were not different between time-control and GLP-1 treated 
swine at any time point before or during ischemia (Table 1). No differences in myocardial 
oxygen consumption were detected between groups at any treatment condition (Table 1).
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Cardiac Effects of Acute GLP-1 Administration
Administration of GLP-1 (7–36) or (9–36) had no effect on left ventricular diastolic filling, 
stroke volume, cardiac output or ejection fraction over the 1.0 to 10.0 pmol/kg/min dose 
range prior to the induction of myocardial ischemia (Table 2). However, during regional 
ischemia GLP-1 (7–36) treatment was significantly associated with increased left ventricular 
end diastolic volume (75 ± 1 vs. 92 ± 5 mL; P = 0.016), and stroke volume (32 ± 6 vs. 48 ± 
6 mL; P = 0.040), without differences in end systolic volume or ejection fraction relative to 
time control animals (Table 2). These alterations in cardiac function were also evident when 
analyzed as absolute changes relative to their respective baseline values (Figure 2). One of 
the most striking findings of this study is the approximate 2 L/min increase in cardiac output 
(P = 0.015 within group; P < 0.001 relative to time control) observed in GLP-1 (7–36) 
treated swine during regional ischemia (Figure 2D). This effect was specific to the (7–36) 
peptide, as these variables were unaffected by the onset of myocardial ischemia in time-
control or (9–36) treated swine.
Steady state pressure-volume loops demonstrating the effect of GLP-1 administration at the 
10 pmol/kg/min dose before and during regional ischemia are presented in Figure 3. These 
loops, presenting averaged pressure-volume data from representative animals, demonstrate 
the lack of an effect of regional ischemia on the left ventricular pressure volume relationship 
under control conditions (Figure 3A). To demonstrate the effects of a classic positive 
inotropic (contractility) and chronotropic (heart rate) response in our preparation, left 
ventricular pressure-volume loops were determined during the administration of intravenous 
epinephrine (10µg/min) in one animal under normal perfusion conditions (Figure 3B). 
Epinephrine produced a marked upward-leftward shift in the pressure-volume loop as a 
result of substantial increases in ventricular systolic pressure (~200 mmHg) and decreases in 
end-systolic and end-diastolic volumes (consequence of heart rates >200 beats/min). Note 
the change in scale of Figure 3B; the dashed line represents the maximal Y scale value of 
other panels. Consistent with previous data [28], GLP-1 (9–36) had no effect on pressure 
volume parameters in normal or ischemic hearts (Figure 3D). In contrast, infusion of GLP-1 
(7–36) (10 pmol/kg/min) during regional myocardial ischemia resulted in diminished left 
ventricular pressure generation and a notable right shift of the pressure-volume relationship; 
i.e. increased left ventricular end-diastolic volume (preload) (Figure 3C).
Effects of GLP-1 peptides on Ees and V0 are found in Table 2. Neither GLP-1 (7–36) nor 
(9–36) influenced Ees at any dose, regardless of experimental condition. Despite the lack of 
change in slope of ESPVR, GLP-1 (7–36) significantly increased V0 at the 10.0 
pmol/kg/min dose, both before and during regional myocardial ischemia (Table 2). V0 was 
unchanged in time-control and GLP-1 (9–36) treated swine. Plotting the relationship 
between cardiac output and end-diastolic volume (Frank-Starling relationship) during 
regional ischemia demonstrates that the increase in cardiac output in GLP-1 (7–36) treated 
swine is directly related to increases in end-diastolic volume (preload) (Figure 4), without 
any apparent contribution from direct effects on contractility. Examination of the time 
constant of ventricular relaxation (Tau ½) suggests that administration of GLP-1(7–36) 
improved diastolic function during LCX occlusion (Table 2). In contrast, Tau ½ tended to 
worsen with LCX occlusion in time control and GLP-1 (9–36) treated animals.
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To assess whether the effects of GLP-1 (7–36) are mediated centrally, additional studies 
were performed in the presence of the non-depolarizing ganglionic blocker hexamethonium 
(n=3). Results of these studies are included in Figure 4 and demonstrate that both cardiac 
output and end diastolic volume are elevated in the ischemic heart with GLP-1 (7–36) 
treatment regardless of hexamethonium administration.
Additional examination of the effects of GLP-1 on cardiac efficiency (cardiac output (L/
min) × mean arterial pressure (mmHg)) / myocardial oxygen consumption (µl O2 min/g) 
demonstrated no effect of vehicle, GLP-1 (7–36) or (9–36) administration under baseline-
control conditions (Figure 5). However, cardiac efficiency was significantly augmented by 
GLP-1 (7–36) administration during regional myocardial ischemia (Figure 5). GLP-1 (9–36) 
had no effect on cardiac efficiency during ischemia.
DISCUSSION
This investigation examined the effects of systemically infused GLP-1 (7–36) and (9–36) on 
systemic hemodynamics, coronary flow and preload-dependent and -independent measures 
of cardiac function in normal and ischemic hearts. Neither GLP-1 isoform had any effect on 
systemic pressure, coronary blood flow or cardiac function in normally perfused hearts 
relative to saline infused time-controls. Moreover, GLP-1 (9–36) had no effect on any 
measured cardiovascular parameter in normal or ischemic hearts. In contrast, the induction 
of regional ischemia during GLP-1 (7–36) administration produced significant reductions in 
systemic blood pressure ~20mmHg and increased cardiac output and efficiency. Pressure 
volume analyses revealed that this (7–36)-mediated increase in cardiac performance was not 
associated with any change in myocardial contractility (as assessed by ESPVR) but was 
accompanied by a significant increase in left ventricular end diastolic volume and an 
increase in volume axis intercept (V0). Together these observations demonstrate that acute 
administration of GLP-1 (7–36) significantly augments cardiac output during regional 
myocardial ischemia via increases in ventricular preload, independent of changes in cardiac 
inotropy (i.e. Frank-Starling mechanism). The findings further indicate that GLP-1 (9–36) is 
unlikely to significantly contribute to improvements in cardiovascular function produced by 
GLP-1(7–36) in ischemic hearts.
Hemodynamic effects of GLP-1 (7–36)
Consistent with previous studies from our laboratory and others [23;24;28], we found that 
short-term treatment with GLP-1 (7–36) had no effect on coronary flow or myocardial 
oxygen consumption under any experimental condition (Table 1). Therefore, improvements 
in cardiac function observed in response to GLP-1 (7–36) cannot be the result of differences 
in myocardial perfusion. GLP-1 (7–36) also had no effect on systolic, diastolic or mean 
blood pressure relative to identically handled time control animals in non-ischemic hearts. 
This lack of a pressor effect in otherwise healthy hearts is consistent with previous 
investigations in human subjects [7;24;32;33;35], but contrasts findings in rodent models 
which largely report hypertensive effects of GLP-1 [4–6;8;15;19;39]. However, we did 
observe significant reductions in blood pressure in GLP-1 (7–36) treated swine during 
regional myocardial ischemia (Figure 1). This hypotensive effect has also been reported by 
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other labs in the setting of various pathologic conditions such as ischemia-reperfusion 
injury, myocardial infarction and heart failure [27;28;35].
Inotropic effects of GLP-1 (7–36)
Prior evidence supports the ability of GLP-1 based therapies to augment preload-dependent 
indices of cardiac function (e.g. dP/dt, developed pressure, cardiac output) in ischemic and 
failing hearts [3;27;28;32;41]. This effect is also evident in the current studies by the marked 
increase in cardiac output in GLP-1 (7–36) treated swine following the induction of regional 
myocardial ischemia (Figure 2D). However, no prior study has directly assessed preload-
independent measures of cardiac contractility in response to GLP-1 to distinguish true 
inotropic effects from Frank-Starling effects. This distinction has important implications for 
the clinical circumstances where these effects can be used to advantage, or importantly 
where the true nature of the effects might imply adverse outcomes. In order to examine this 
key issue, we employed high sensitivity pressure volume catheters to obtain end systolic 
pressure volume relationships (ESPVR), the “gold-standard” measure of cardiac inotropy 
[9;34]. ESPVR is experimentally measured by progressive reductions in ventricular preload 
via transient balloon occlusion of the inferior vena cava, such that increases in contractility 
(inotropy) augment pressure at a given ventricular volume resulting in an elevation in the 
slope of ESPVR (see effect of 10µg/min epinephrine in Figure 3B). In the current study, 
GLP-1 (7–36) did not affect the slope of ESPVR at any dose in normal hearts, or following 
acute ligation of the left circumflex coronary artery. These findings indicate that GLP-1 
mediated increases in cardiac output observed following the onset of acute, regional 
ischemia are independent of changes in myocardial contractility. However, our data do not 
address the potential inotropic effects of longer term GLP-1 administration, an avenue 
meriting future studies.
Starling effects of GLP-1 (7–36)
Preload-independent assessments of cardiac contractility include two key measurements; 
slope of ESPVR and the volume axis intercept (V0 – ventricular volume at zero pressure). 
Under controlled conditions, a shift in V0 indicates a volume dependent action on contractile 
force making V0 a suitable index of the Frank-Starling mechanism. We found that 10.0 
pmol/kg/min GLP-1 (7–36) administration significantly increased V0 in both normal and 
ischemic hearts (Table 2). Additionally, GLP-1 (7–36) treatment significantly increased left 
ventricular end diastolic volume (Figure 2A) with no significant change in end systolic 
volume (Figure 2B) during regional ischemia. This phenomenon is readily apparent by 
examination of averaged left ventricular pressure-volume relationships at the 10.0 
pmol/kg/min dose (vehicle or GLP-1 analogues) during normal perfusion and ischemia 
(Figure 3) and by examination of the relationship between end-diastolic volume and cardiac 
output in Figure 4. This effect was maintained in the presence of the non-depolarizing 
ganglionic blocker hexamethonium (Figure 4). Taken together, these findings indicate that 
acute administration of GLP-1 (7–36) significantly increases in cardiac output mediated 
through a preload-dependent, Frank-Starling effect via effects on the heart itself as opposed 
to via centrally mediated processes.
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Since the initial description of load-dependent changes in cardiac contractile force [20], 
numerous molecular phenomena have been implicated as the mechanism of cardiac 
heteromeric autoregulation (i.e. Frank-Starling Responses) [1;9;10;12–14;16;17;32]. While 
the precise mechanisms responsible for this effect of GLP-1 (7–36) remain unclear it is 
important to point out that the increases in cardiac output occurred without concomitant 
increase in myocardial oxygen consumption; i.e. GLP-1 (7–36) augmented cardiac 
efficiency during ischemia (Figure 5). We postulate this effect is related at least in part to 
optimization of the myocellular contractile apparatus (i.e. Starling effect) and/or 
energetically favorable alterations in myocardial substrate metabolism (i.e. augmented 
glucose uptake) [18;22;23;25;37]. Understanding of these mechanisms could have 
significant therapeutic relevance for development of energetically favorable therapies for 
heart failure.
CONCLUSION
Short-term systemic exposure to GLP-1 (7–36) augments cardiac output under conditions of 
ischemia through increases in preload (Frank-Starling mechanism) without direct effects on 
contractility or other centrally mediated phenomena. This “Starling” response was facilitated 
by enhanced cardiac relaxation as indicated by elevations in V0. Neither GLP-1 (7–36) nor 
(9–36) affected coronary flow or systemic pressure regulation, and in contrast to intact 
GLP-1 (7–36), the GLP-1 (9–36) fragment did not exert any effects on cardiac output during 
ischemia. Taken together, these results support a role for GLP-1 (7–36) in enhancing cardiac 
output under conditions of regional myocardial ischemia. This enhancement is energetically 
favorable as the process is a passive response resulting from facilitation of diastolic filling as 
opposed to an active inotropic mechanism.
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Figure 1. 
Data (mean±SEM) describing changes in SBP (Panel A), DBP (Panel B), MBP (Panel C) or 
HR (Panel D), presented as a change relative to within treatment group baseline. All data are 
presented for all animals receiving GLP-1 (7–36) infusion, GLP-1 (9–36) infusion or 
infusion rate matched saline-infused time controls. *p<0.05 vs. identically handled, time 
control.
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Figure 2. 
Data (mean±SEM) describing changes in EDV (Panel A), ESV (Panel B), SV (Panel C) or 
CO (Panel D), presented as a change relative to within treatment group baseline. All data are 
presented for all animals receiving GLP-1 (7–36) infusion, GLP-1 (9–36) infusion or 
infusion rate matched saline-infused time controls. *p<0.05 vs. identically handled, time 
control.
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Figure 3. 
Representative pressure-volume loops from saline infused time controls (Panel A), GLP-1 
(7–36) (Panel C) and GLP-1 (9–36) (Panel D) treated animals at the highest infusion rate (10 
pmol/kg/min) during normal perfusion (solid line; black) and subsequent to induction of 
regional myocardial ischemia (interrupted line; gray). Each representative loop is the result 
of averaging 3 consecutive loops from 3 separate animals during plateau of responses during 
the relevant, presented conditions. Panel B provides representative data from a single animal 
(3 averaged loops per condition) demonstrating effect of epinephrine on pressure volume 
relationships (interrupted gray line) during normal myocardial perfusion. Note the change in 
scale of Panel B; the dashed line represents the maximal Y scale value of other panels.
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Figure 4. 
Summary plot for the relationships between end-diastolic volume (EDV) and cardiac output 
(CO) during regional myocardial ischemia and exposure to study treatments.
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Figure 5. 
Effects of GLP-1 therapies on cardiac efficiency (cardiac output per unit oxygen 
consumption) at baseline and during ischemia. Data are presented as mean±SEM *p<0.05 
GLP-1 (7–36) vs. saline and vs GLP-1 (9–36).
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Table 1
Effects of GLP-1 (7–36) vs. (9–36) on systemic hemodynamics and metabolism
Time-Control GLP-1 (7–36) GLP-1 (9–36)
Systolic Blood Pressure (mmHg)
  Baseline 110±9 136± 4 127±9
  1.5 pmol/kg/min 104±9 125±5 114±12
  3.0 pmol/kg/min 99±9 118±6 109±12
  10.0 pmol/kg/min 97±9 114±8 104 ±13
  LCX Occlusion 92± 8 92±10† 98±12
Diastolic Blood Pressure (mmHg)
  Baseline 82±7 93±3 86±6
  1.5 pmol/kg/min 76±6 87±4 80±6
  3.0 pmol/kg/min 73±5 82±4 77±7
  10.0 pmol/kg/min 71±6 80±6 72±8
  LCX Occlusion 67±6 68±9† 71±9
Mean Blood Pressure (mmHg)
  Baseline 95±8 113± 4 105±6
  1.5 pmol/kg/min 89±8 105±4 95±8
  3.0 pmol/kg/min 82± 8 99±5 92±9
  10.0 pmol/kg/min 83±8 95±7 86±11
  LCX Occlusion 78±7 78±10† 83± 10
Heart Rate (beats/min)
  Baseline 80±8 63± 4 67±10
  1.5 pmol/kg/min 81±11 68±5 75±10
  3.0 pmol/kg/min 73±7 69±5 79± 13
  10.0 pmol/kg/min 71±11 80±12 75±11
  LCX Occlusion 72±9 87± 10 77± 11
Coronary Blood Flow (ml/min/g)
  Baseline 0.47± 0.06 0.46 ± 0.03 0.43 ± 0.06
  1.5 pmol/kg/min 0.43± 0.05 0.39 ± 0.02 0.36 ± 0.06
  3.0 pmol/kg/min 0.35± 0.04 0.34 ± 0.02† 0.33 ± 0.05
  10.0 pmol/kg/min 0.40± 0.03 0.33 ± 0.03† 0.29 ± 0.06
  LCX Occlusion 0.30± 0.05 0.30 ± 0.03† 0.27 ± 0.07
Myocardial O2 Consumption (µl O2/min/g)
  Baseline 50±6 54±3 48±7
  1.5 pmol/kg/min 50±4 48±2 41±6
  3.0 pmol/kg/min 43±3 42±3 39±6
  10.0 pmol/kg/min 41±1 40±3 36±7
  LCX Occlusion 36±6 40±5 36±8
Values are mean ± SE for Time-Control (n = 5), GLP-1 (7–36) (n = 9; n = 5 for LCX occlusion) and GLP-1 (9–36) (n = 5).
†
P < 0.05 vs. baseline value (same treatment).
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‡
P < 0.05 vs. infusion rate matched, saline infused time controls.
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Table 2
Effects of GLP-1 (7–36) vs. (9–36) on cardiac contractile function
Time-Control GLP-1 (7–36) GLP-1 (9–36)
LV End Diastolic Volume (ml)
  Baseline 78± 1 82 ± 3 78 ± 1
  1.5 pmol/kg/min 75 ± 1 79 ± 4 71 ± 4
  3.0 pmol/kg/min 75±3 79 ± 4 68 ± 5
  10.0 pmol/kg/min 73±2 69 ± 4 66 ± 7
  LCX Occlusion 75± 1 92 ± 5‡ 76 ± 6
LV End Systolic Volume (ml)
  Baseline 41±5 42±5 44±5
  1.5 pmol/kg/min 40±6 41±5 46±4
  3.0 pmol/kg/min 40±6 42±5 45±3
  10.0 pmol/kg/min 36±6 34±4 43±4
  LCX Occlusion 43±6 49±6 48±3
LV Stroke Volume (ml)
  Baseline 37±5 40±3 34 ±4
  1.5 pmol/kg/min 36±5 37±4 24±5
  3.0 pmol/kg/min 36±6 37±4 23±5
  10.0 pmol/kg/min 37±6 34 ±6 22±5
  LCX Occlusion 32±6 48± 6‡ 27±6
Cardiac Output (ml/min)
  Baseline 2838±99 2531 ± 271 2324±529
  1.5 pmol/kg/min 2689±74 2524 ± 331 1675±262
  3.0 pmol/kg/min 2510±280 2676 ± 429 1558±201
  10.0 pmol/kg/min 2474 ±255 2576 ± 575 1442±213
  LCX Occlusion 2227±315 4319 ± 908†‡ 1902±329
LV Ejection Fraction (%)
  Baseline 48± 6 49 ± 5 44±6
  1.5 pmol/kg/min 48±7 48 ± 5 34± 6
  3.0 pmol/kg/min 48±8 48 ± 5 33± 6
  10.0 pmol/kg/min 51±9 49 ± 6 33±6
  LCX Occlusion 43±8 50 ± 6 35±6
End Systolic Pressure Volume Relationship (mmHg/ml)
  Baseline 11±3 11±4 15±4
  1.5 pmol/kg/min 16± 5 17±6 15±6
  3.0 pmol/kg/min 17±5 17±4 14±3
  10.0 pmol/kg/min 16±7 20 ±5 20±9
  LCX Occlusion 12±4 13±3 13± 0
Volume Axis Intercept (ml)
  Baseline 7 ± 2 9 ± 2 4 ± 4
  1.5 pmol/kg/min 7± 2 9 ± 6 5 ± 3
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Time-Control GLP-1 (7–36) GLP-1 (9–36)
  3.0 pmol/kg/min 8 ± 2 19 ± 2‡ 11 ± 5
  10.0 pmol/kg/min 8±2 24 ± 4‡ 7 ± 1
  LCX Occlusion 9± 2 26 ± 8‡ 9 ± 0
Tau ½
  Baseline 43±7 42 ± 3 48 ± 13
  1.5 pmol/kg/min 48±9 43 ± 4 52 ± 11
  3.0 pmol/kg/min 44±8 44 ± 5 55 ± 14
  10.0 pmol/kg/min 64± 13 45 ± 8 63 ± 17
  LCX Occlusion 60± 14 32 ± 3 83 ± 27
Values are mean ± SE for Time-Control (n = 5), GLP-1 (7–36) (n = 5) and GLP-1 (9–36) (n = 5).
†
P < 0.05 vs. baseline value (same treatment).
‡
P < 0.05 vs. infusion rate matched, saline infused time controls.
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